Description
HS-10541 is an investigational drug currently being studied in clinical trials. It is being evaluated as a potential treatment for advanced solid tumors, including colorectal cancer, specifically in patients whose tumors have a KRAS G12C mutation. The trials are in the early phase (Phase 1), meaning the primary goal is to determine the safe dosage and understand how the drug is processed by the body (pharmacokinetics). Researchers are also looking for early signs that the drug might be effective (preliminary efficacy). HS-10541 is being tested both by itself (monotherapy) and in combination with other cancer treatments.
Mechanism of Action
HS-10541 is being investigated for its potential to treat cancers with a specific KRAS G12C mutation. KRAS is a gene that can mutate and contribute to cancer growth. The specific way HS-10541 works (its mechanism of action) is still being studied in clinical trials. It is designed to target processes involved in tumor growth, particularly in the context of this specific mutation.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.